共 331 条
- [1] Aberle JH(2015)Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015(1). Safety of CYD-TDV dengue vaccine Wkly Epidemiol Rec 90 421-423
- [2] Koblischke M(2018)CD4 T cell responses to flaviviruses J Clin Virol 108 126-131
- [3] Stiasny K(2010)Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification PLoS Pathog 6 e1000790-507
- [4] Balsitis SJ(2013)The global distribution and burden of dengue Nature 496 504-1365
- [5] Williams KL(2014)Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial Lancet 384 1358-166
- [6] Lachica R(2012)Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice PLoS One 7 e34602-398
- [7] Flores D(2016)Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice Sci Rep 6 30648-1174
- [8] Kyle JL(2016)Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV(R)) in children Expert Rev Vaccines 15 153-748
- [9] Mehlhop E(2011)Dengue vaccines: progress and challenges Curr Opin Immunol 23 391-35
- [10] Johnson S(2007)A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles J Gen Virol 88 1169-31